Category Regulatory

Clarametyx Biosciences Bolsters Executive Team to Drive Clinical Development Progress

Clarametyx Biosciences Enhances Leadership Team to Advance Clinical Development Initiatives Clarametyx Biosciences, Inc., a clinical-stage biotechnology company focused on developing immune-enabling therapies and vaccines to combat biofilm-driven chronic respiratory diseases, has announced key leadership promotions within its executive team. These…

Read MoreClarametyx Biosciences Bolsters Executive Team to Drive Clinical Development Progress

Tenpoint Therapeutics and PHIL Launch YUVEZZI™ Cash Program to Expand Access to Presbyopia Treatment

Tenpoint Therapeutics and PHIL Collaborate to Introduce YUVEZZI™ Direct-to-Patient Cash Program, Improving Access and Affordability for Presbyopia Care Tenpoint Therapeutics, a company focused on advancing innovative treatments in eye care, has partnered with PHIL Inc. to introduce a new Direct-to-Patient…

Read MoreTenpoint Therapeutics and PHIL Launch YUVEZZI™ Cash Program to Expand Access to Presbyopia Treatment

SV Health Investors Acquires EpiVax to Strengthen Immunology Portfolio

SV Health Investors Completes Acquisition of EpiVax SV Health Investors has announced the acquisition of EpiVax, Inc., a well-established contract research organization (CRO) specializing in immunogenicity risk assessment for pharmaceutical and biotechnology companies. The transaction marks a new platform investment…

Read MoreSV Health Investors Acquires EpiVax to Strengthen Immunology Portfolio

RefleXion Gains Expanded Medicare Reimbursement Coverage for SCINTIX Cancer Therapy

RefleXion Achieves Broader Medicare Reimbursement Approval for SCINTIX Cancer Therapy RefleXion Medical has announced a significant advancement in reimbursement support for its innovative SCINTIX® autonomous radiotherapy platform, as Noridian Healthcare Solutions, LLC has established payment rates for the therapy in…

Read MoreRefleXion Gains Expanded Medicare Reimbursement Coverage for SCINTIX Cancer Therapy

Bristol Myers Squibb Marks a Decade of GAAP Progress, Expanding Efforts to Advance Equity in Multiple Myeloma Care

Bristol Myers Squibb Strengthens and Expands Commitment to Advancing Equitable Care in Multiple Myeloma as GAAP Initiative Reaches Ten Years Bristol Myers Squibb (NYSE: BMY), a recognized leader in oncology, has announced a significant evolution of its long-standing “Standing in…

Read MoreBristol Myers Squibb Marks a Decade of GAAP Progress, Expanding Efforts to Advance Equity in Multiple Myeloma Care

Sub-Q Bionics Secures $1.5 Million Pre-Seed Funding to Accelerate Innovative Lymphedema Treatment Solution

Sub-Q Bionics Raises $1.5 Million Pre-Seed Round to Accelerate Development of Next-Generation Lymphedema Care Technology Sub-Q Bionics, an emerging innovator in the medical device space, has taken a significant step forward in its mission to transform care for patients living…

Read MoreSub-Q Bionics Secures $1.5 Million Pre-Seed Funding to Accelerate Innovative Lymphedema Treatment Solution

CorVista Health Showcases High-Sensitivity Noninvasive Detection of CAD, Including INOCA, at ACC.26

CorVista Health Unveils Machine Learning–Driven Noninvasive Approach to Detect Cardiac Ischemia at ACC.26 CorVista Health has announced promising new clinical data supporting a novel, noninvasive diagnostic approach for detecting cardiac ischemia using physiologic signal analysis combined with advanced machine learning.…

Read MoreCorVista Health Showcases High-Sensitivity Noninvasive Detection of CAD, Including INOCA, at ACC.26

Biocytogen Licenses RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform to Taisho Pharmaceutical

Biocytogen Enters Platform Licensing Agreement with Taisho to Expand Use of RenNano® Antibody Discovery Technology Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a global biotechnology company recognized for its innovation in antibody-based drug discovery, has announced a new strategic collaboration with Taisho…

Read MoreBiocytogen Licenses RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform to Taisho Pharmaceutical